钙蛋白酶小亚基 1 蛋白在癌症幸存者预后中的作用及其与临床病理的相关性。
Calpain Small Subunit 1 Protein in the Prognosis of Cancer Survivors and Its Clinicopathological Correlation.
机构信息
Department of Oncology, The First People's Hospital of Neijiang, Neijiang 641000, Sichuan Province, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou 570100, Hainan Province, China.
出版信息
Biomed Res Int. 2019 Nov 26;2019:8053706. doi: 10.1155/2019/8053706. eCollection 2019.
UNLABELLED
. Calpain small subunit 1 (Capn4) is implicated in tumorigenesis and plays a key role in multiple tumors. This study aimed to fully illustrate the prognostic value of Capn4 protein in cancer patients.
METHODS
A systematic search was conducted against several online databases. Hazard ratios (HRs) or odds ratio (ORs) were used to investigate the relationship between Capn4 protein expression and prognosis as well as clinical parameters in cancer survivors.
RESULTS
Eleven studies involving 1775 patients were identified. Overall, the results showed that Capn4 protein was associated with poor prognosis of overall survival (OS) (HR=1.74; 95% CI:1.47-2.01; <0.001) and event-free survival (EFS) (HR=1.73; 95% CI:1.39-2.07; <0.001) and event-free survival (EFS) (HR=1.73; 95% CI:1.39-2.07; <0.001) and event-free survival (EFS) (HR=1.73; 95% CI:1.39-2.07; <0.001) and event-free survival (EFS) (HR=1.73; 95% CI:1.39-2.07; <0.001) and event-free survival (EFS) (HR=1.73; 95% CI:1.39-2.07; <0.001) and event-free survival (EFS) (HR=1.73; 95% CI:1.39-2.07; <0.001) and event-free survival (EFS) (HR=1.73; 95% CI:1.39-2.07; <0.001) and event-free survival (EFS) (HR=1.73; 95% CI:1.39-2.07; <0.001) and event-free survival (EFS) (HR=1.73; 95% CI:1.39-2.07.
CONCLUSIONS
Expression of Capn4 protein is associated with cancer survival and clinicopathologic characteristics in patients.
目的
全面阐明 Capn4 蛋白在癌症患者中的预后价值。
方法
系统检索多个在线数据库。使用风险比 (HR) 或比值比 (OR) 来研究 Capn4 蛋白表达与癌症幸存者预后及临床参数之间的关系。
结果
共纳入 11 项研究，涉及 1775 例患者。总体而言，结果表明 Capn4 蛋白与总生存期 (OS) (HR=1.74; 95% CI:1.47-2.01; <0.001) 和无事件生存期 (EFS) (HR=1.73; 95% CI:1.39-2.07; <0.001) 不良预后相关，无事件生存期 (EFS) (HR=1.73; 95% CI:1.39-2.07; <0.001) 不良预后相关，无事件生存期 (EFS) (HR=1.73; 95% CI:1.39-2.07; <0.001) 不良预后相关，无事件生存期 (EFS) (HR=1.73; 95% CI:1.39-2.07; <0.001) 不良预后相关，无事件生存期 (EFS) (HR=1.73; 95% CI:1.39-2.07; <0.001) 不良预后相关，无事件生存期 (EFS) (HR=1.73; 95% CI:1.39-2.07; <0.001) 不良预后相关，无事件生存期 (EFS) (HR=1.73; 95% CI:1.39-2.07; <0.001) 不良预后相关，无事件生存期 (EFS) (HR=1.73; 95% CI:1.39-2.07; <0.001) 不良预后相关，无事件生存期 (EFS) (HR=1.73; 95% CI:1.39-2.07; <0.001) 不良预后相关，无事件生存期 (EFS) (HR=1.73; 95% CI:1.39-2.07; <0.001) 不良预后相关。
结论
Capn4 蛋白的表达与癌症患者的生存和临床病理特征有关。
Zotero 插件